Overview

Safety, Tolerability, and Efficacy of 21 Days Dermal Application of MRX-6 on Mild to Moderate Contact Dermatitis

Status:
Completed
Trial end date:
2014-03-01
Target enrollment:
Participant gender:
Summary
A Double-blind, Vehicle-controlled Study to Assess the Safety, Tolerability, and Efficacy of Three Weeks of Daily Dermal Application of MRX-6 or steroid on the Treatment of Mild to Moderate Allergic Contact Dermatitis of the Hand and Forearm. Total number of patients: up to 80.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Hadassah Medical Organization
Collaborator:
Morria Biopharmaceuticals PLC